Inactivation of TP53 and RB1 are common genetic alterations in SCLC.[6] Other signaling pathways are frequently interrupted such as Notch signaling and nuclear factor kappa light chain enhancer of activated B cells signaling.[4, 7] The high mutational burden of SCLC might provide opportunities for the therapeutic intervention.[1a]. Here, TP53 is linked to small cell lung carcinoma.